Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a medical device company focused on treating and transforming the lives of patients suffering from venous and other vascular diseases. This news page aggregates company announcements, clinical trial updates, financial disclosures, and event participation related to NARI stock.
Inari’s news often highlights developments around its thrombectomy technologies and venous interventions. The company has reported on clinical research programs such as the ClotTriever CLOUT Registry for deep vein thrombosis and randomized controlled trials including DEFIANCE and PEERLESS. For example, Inari announced positive PEERLESS results comparing its FlowTriever system to catheter-directed thrombolytics in intermediate-risk pulmonary embolism, with outcomes related to clinical deterioration, ICU use, hospital stay, and readmissions.
Investors and healthcare professionals can use this page to follow updates on regulatory and reimbursement milestones, such as national reimbursement approval in Japan for the ClotTriever Thrombectomy System for DVT and related distribution agreements. News items also cover international initiatives like Inari’s joint venture in Greater China with 6 Dimensions Capital, 120 Capital, and VFLO Medical to expand access to its technologies.
In addition, the feed includes information on Inari’s participation in major healthcare and investor conferences, including presentations at the J.P. Morgan Healthcare Conference, the Jefferies London Healthcare Conference, and analyst and investor meetings aligned with key clinical trial presentations. Financial news, such as quarterly results and guidance updates, is also featured. For ongoing insight into NARI’s clinical, commercial, and corporate developments, readers can consult this page as a centralized source of Inari Medical news.
Drew Hykes will replace Bill Hoffman as Chief Executive Officer of Inari Medical (NASDAQ: NARI), effective January 1, 2023. Hykes, who has been with Inari since 2017, previously served as Chief Operating Officer and Chief Commercial Officer. Under his leadership, Inari has experienced significant growth, evolving from a startup to a public company with over 1,000 employees. The company also announced its second quarter 2022 financial results, highlighting its minimally invasive thrombectomy devices aimed at treating venous diseases.
Inari Medical reported a strong second quarter in 2022, achieving $92.7 million in revenue, a 46% year-over-year increase. The company expanded its U.S. commercial footprint to over 270 territories and received FDA clearance for two new products. Gross profit stood at $82.4 million, resulting in an 88.8% gross margin. However, the operating expenses surged to $91.7 million, leading to a net loss of $10.2 million. Inari reaffirmed its full-year revenue guidance of $360 million to $370 million.
Inari Medical (NASDAQ: NARI) will announce its Q2 2022 financial results on August 3, 2022. A conference call is scheduled for 2:00 PM PT to discuss these results and recent highlights. The company specializes in medical devices for treating venous diseases, offering minimally invasive catheter-based solutions like the ClotTriever and FlowTriever systems, which are FDA-cleared and CE-marked for clot removal. Investors can join the conference call after registering.
Okami Medical Inc. has received FDA 510(k) clearance for its LOBO-7 and LOBO-9 Vascular Occluders, enhancing its LOBO portfolio designed for peripheral vascular interventions. These new devices, along with existing LOBO-3 and LOBO-5, enable efficient blood vessel occlusions, crucial for procedures requiring rapid response in trauma cases. According to the company's leadership, this expansion emphasizes their commitment to innovation in vascular embolization, potentially improving patient outcomes and procedural efficiency.
Summary not available.
Inari Medical (NASDAQ: NARI) reported a strong first quarter for 2022, achieving revenue of $86.8 million, a 51% increase year-over-year. The company treated 8,800 patients, a sequential rise of 14%, and launched the new Intri24 device, enhancing its product line. Despite a net loss of $3.1 million, Inari revised its full-year revenue guidance upward to between $360 million and $370 million. The improved outlook reflects robust growth in U.S. operations and new product introductions.
Inari Medical, Inc. (NASDAQ: NARI) announced its management will present at the Bank of America 2022 Healthcare Conference on May 12, 2022, at 10:40 a.m. PT in Las Vegas. The presentation focuses on the company's innovative solutions for treating venous diseases, including FDA-cleared thrombectomy devices designed to remove large clots effectively. A live audio webcast of the event will be available on the company's website for 90 days under the 'Investor Relations' section.
Inari Medical, Inc. (NASDAQ: NARI) will release its Q1 2022 financial results on May 4, 2022. The company aims to transform the treatment of venous diseases with innovative catheter-based thrombectomy devices. Inari's ClotTriever is FDA 510(k)-cleared for deep vein thrombosis treatment, while FlowTriever is cleared for pulmonary embolism. Following the earnings release, a conference call will be held to discuss financial results and updates. Interested parties can access the live call and webinar via the company's investor relations website.
Inari Medical, Inc. (NASDAQ: NARI) announced the completion of a public offering, selling an additional 300,000 shares after exercising an over-allotment option. The total number of shares sold reached 2,300,000, generating approximately $186.3 million in gross proceeds at a price of $81.00 per share. Major underwriters included BofA Securities and Morgan Stanley. The transaction was conducted under an effective shelf registration statement filed with the SEC.
Inari Medical, Inc. (NASDAQ: NARI) has announced a public offering of 2,000,000 shares at $81.00 per share, expected to close around March 15, 2022. The underwriters have a 30-day option to purchase an additional 300,000 shares. Proceeds from this offering will support Inari’s mission to treat patients with venous diseases using their innovative catheter-based systems. The offering is registered under an effective shelf registration statement filed with the SEC.